



To whom it may concern

November 19, 2009

NanoCarrier Co., Ltd.

Ichiro Nakatomi, Ph.D., President & CEO

(Code No.; 4571 Tokyo Stock Exchange Mothers)

Toshiki Kaura, Head of President's Office

TEL. +81-3-3548-0217

Development of sustained-release docetaxel, a new DDS formulation

NanoCarrier Co., Ltd. has successfully developed a new nanomicellar formulation of sustained-released docetaxel.

Docetaxel-incorporating nanomicelle can adequately control the release rate of docetaxel* from micellar nanoparticles and possibly reduce the adverse effects of docetaxel, such as gastrointestinal toxicities, edema etc., while obtaining its efficacy.

In experimental studies using human cancer models in mice, docetaxel-incorporating micelle showed equal to or better than antitumor effects of conventional docetaxel while there were much less weight losses observed.

Docetaxel-incorporating nanomicelle has the different structure from paclitaxel-incorporating nanomicelle (NK105) which also belongs to the taxane family. We are developing docetaxel-incorporating micelle as a succeeding candidate of NK105 as there is a six years gap of development schedule between this new drug and NK105.

NanoCarrier will perform additional studies for docetaxel-incorporating micelle and move forward with granting licenses to pharmaceutical companies.

*Docetaxel is an anticancer agent that has been marketed by Sanofi-aventis under the brand name of Taxotere® since 1994. This agent is widely used for the treatment of breast cancer, non-small-cell lung cancer, gastric cancer, uterine cancer, ovarian cancer, and prostate cancer. Sales of docetaxel are still strong, with approximately 300 billion yen in the global market. On the other hand, use of this agent is known to produce the following adverse effects: edema, bone-marrow suppression, gastrointestinal disorders (nausea and vomiting), alopecia, hepatic dysfunction, hypersensitivity reaction, and general fatigue.

We believe docetaxel-incorporating micelle can relieve patients of these adverse effects and help them improve quality of life of cancer patients.